Why is Transgene Biotek falling/rising?

As of 05-Sep, Transgene Biotek Ltd is experiencing a decline in its stock price, currently at 3.96, reflecting a decrease of 0.05 or 1.25%. The stock has fallen after two consecutive days of gains, and while it is performing inline with its sector today, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has shown a modest increase of 2.06%, but it has significantly underperformed over the longer term, with a year-to-date decline of 42.02% and a one-year drop of 52.86%. There is a noted increase in investor participation, with delivery volume rising by 9.62% against the five-day average, suggesting some interest despite the overall negative performance. Unfortunately, there is no information available regarding positive or negative factors impacting the stock.
In the broader market context, the stock's short-term performance of +2.06% over the past week outpaces the Sensex, which has gained only 1.13% in the same period. However, the stark contrast in longer-term performance is evident, as Transgene Biotek has declined by 42.02% year-to-date compared to the Sensex's modest gain of 3.29%. This disparity highlights the challenges faced by Transgene Biotek in attracting sustained investor confidence, particularly in light of its significant losses over the past year and beyond.